Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma

Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients

Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) With Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)